Correlation Engine 2.0
Clear Search sequence regions

Sizes of these terms reflect their relevance to your search.

The anti-HER2-drug conjugate trastuzumab deruxtecan (T-DXd) was effective in HER2-low breast cancer. ©2020 American Association for Cancer Research.


Trastuzumab Deruxtecan Is Effective in HER2-Low Breast Cancer. Cancer discovery. 2020 Apr;10(4):488

Expand section icon Mesh Tags

Expand section icon Substances

PMID: 32111601

View Full Text